Vipul Kumar

Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer

R. Bose, E. Small, S. Porten, 2023, Frontiers in Oncology.

Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma PatientsTreated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.

Julian C. Hong, M. Meng, R. Bose, 2023, Clinical genitourinary cancer.

Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer.

M. Cooperberg, S. Porten, I. de Kouchkovsky, 2024, Journal of Nuclear Medicine.